Search results
Showing 991 to 1005 of 1026 results for drug therapy
NICE has today (20 April 2021) published draft guidance recommending trastuzumab deruxtecan for use in the Cancer Drugs Fund (CDF) for treating a type of breast cancer called HER2 positive breast cancer which can’t be surgically removed or which has spread to other parts of the body.
NICE draft guidance recommends abemaciclib for advanced breast cancer
NICE has today published draft guidance which recommends twice-daily pill abemaciclib (also called Verzenios and made by Eli Lilly) as an option for adults with a type of breast cancer called hormone receptor-positive, HER2-negative breast cancer which has spread to other parts of the body.
NICE draft guidance recommends apalutamide for treating prostate cancer
NICE has today (8 September 2021) published final draft guidance which now recommends apalutamide (also called Erleada and made by Janssen) plus androgen deprivation therapy for treating prostate cancer in adults
NICE and PHE publish comprehensive draft guideline to tackle the health burden of smoking
Healthcare staff should give clear and up-to-date information on e-cigarettes to people who are interested in using them to stop smoking, according to draft NICE guideline recommendations out for consultation today. NICE worked with Public Health England to develop this guideline
NICE approves ground-breaking cholesterol-lowering drug inclisiran
NICE has today (1 September 2021) issued draft final guidance recommending the novel anti-cholesterol drug inclisiran (Leqvio and made by Novartis) for people with primary hypercholesterolaemia or mixed dyslipidaemia who have already had a cardiovascular event such as a heart attack or stroke.
NICE final draft guidance approves life-changing gene therapy for treating spinal muscular atrophy
A new and potentially curative one-off gene therapy for babies with the rare genetic disorder spinal muscular atrophy (SMA) is set to become the most expensive treatment ever approved by NICE.
NICE approves routine use of drug combination for advanced breast cancer
Another life-extending drug combination for some people with advanced breast cancer will now be available for routine use in the NHS following its approval by NICE in final draft guidance published today (23 September 2022).
Hundreds of people set to benefit after NICE recommends first personalised immunotherapy for lymphoma
Nasal spray medicine for treatment-resistant depression not recommended by NICE
More evidence on the clinical and cost effectiveness of esketamine needed
NICE sets out new advice to treat gastro-oesophageal reflux disease (GORD) more effectively
Healthcare professionals should reassure parents that reflux is very common in well infants and does not require treatment, but should be alert to red flag symptoms which may suggest GORD or other disorders.
Chemotherapy-free treatment option to be offered to patients with England's most common leukaemia
Acalabrutinib, taken as a twice daily tablet, is recommended as an option for adults with untreated chronic lymphocytic leukaemia.
NICE has approved the use of nalmefene to help people who are dependent on alcohol to cut down on the amount they drink.
Children with a rare, fatal, genetic disorder will be able to benefit from a new one-off treatment under new NICE guidance.
Breast cancer patients to have further NICE-approved drug combination option on Cancer Drugs Fund
Another potentially life-extending drug combination for some people with advanced breast cancer will now be available on the Cancer Drugs Fund (CDF) following its approval by NICE in final guidance published today (15 January 2020).
NICE has today (4 February 2020) published the outcome of the appeal against its final draft guidance (FAD) on erenumab (also called Aimovig and made by Novartis) for preventing chronic migraine.